BMC RheumatologyPub Date : 2026-01-07DOI: 10.1186/s41927-025-00608-6
Anastasia Suslow, Romy Lauer, Uta Kiltz, Chantal Giehl, Kerstin Hellwig, Theresa Oganowski, Thomas Grüter, Maria Zacharopoulou, Andreas Stallmach, Anika Franz, Ursula Marschall, Joachim Saam, Catharina Schumacher, Stephanie Stock, Dusan Simic, Arim Shukri, Kathrin Schlößler, Ina Carola Otte, Horst Christian Vollmar
{"title":"Factors influencing vaccination decisions in patients with inflammatory rheumatic and musculoskeletal disease: a qualitative approach.","authors":"Anastasia Suslow, Romy Lauer, Uta Kiltz, Chantal Giehl, Kerstin Hellwig, Theresa Oganowski, Thomas Grüter, Maria Zacharopoulou, Andreas Stallmach, Anika Franz, Ursula Marschall, Joachim Saam, Catharina Schumacher, Stephanie Stock, Dusan Simic, Arim Shukri, Kathrin Schlößler, Ina Carola Otte, Horst Christian Vollmar","doi":"10.1186/s41927-025-00608-6","DOIUrl":"10.1186/s41927-025-00608-6","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) have an increased risk of infections due to immunosuppression and autoimmune disease. While vaccinations are an important preventive strategy, vaccination coverage remains insufficient in Germany. The study aimed to identify barriers and facilitators for vaccination uptake from the perspective of iRMD patients, general practitioners (GPs), and rheumatologists.</p><p><strong>Methods: </strong>We conducted semi-structured, qualitative interviews with German iRMD patients (n = 15), GPs (n = 10), and rheumatologists (n = 5). Data were analyzed using Kuckartz's structured content analysis. The analysis focused on attitudes towards vaccination, information needs, decision-making, and perceived role distribution in care.</p><p><strong>Results: </strong>A trust-based doctor-patient relationship and consistent, comprehensible information promoted willingness to vaccinate. Barriers included uncertainties regarding immunosuppressants, unclear responsibilities between GPs and rheumatologists, and inconsistent or conflicting medical recommendations. Patients desired a proactive approach from physicians and clearly assigned responsibilities. Physicians emphasized interprofessional exchange but stated time and structural challenges.</p><p><strong>Conclusion: </strong>The results underline the importance of coordinated communication and clear responsibilities in the vaccination process for iRMD patients. To increase vaccination rates among patients with iRMD, the focus should be on targeted information services, improved allocation of tasks between GPs and rheumatologists, timely scheduling of vaccinations (ideally before initiating immunosuppressive therapy), clear responsibilities for initiating and coordination of vaccination, and a structured, transparent flow of evidence-based information between specialists. The results provide a basis for the development of practical intervention strategies to increase vaccination uptake in this high-risk group.</p><p><strong>Trial registration: </strong>The study was registered at the German Register of Clinical Studies (DRKS): https://drks.de/search/de/trial/DRKS00031559 (Registration Date: 28.08.2023).</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":" ","pages":"11"},"PeriodicalIF":2.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2025-12-30DOI: 10.1186/s41927-025-00611-x
Yuji Kishimoto, Kazuki Nakazawa, Manami Uemura, Koji Kuranobu
{"title":"Add-on iguratimod or tacrolimus in methotrexate in patients with rheumatoid arthritis not achieving remission with methotrexate: a retrospective propensity score-matched study.","authors":"Yuji Kishimoto, Kazuki Nakazawa, Manami Uemura, Koji Kuranobu","doi":"10.1186/s41927-025-00611-x","DOIUrl":"10.1186/s41927-025-00611-x","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":" ","pages":"12"},"PeriodicalIF":2.5,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12859856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2025-12-29DOI: 10.1186/s41927-025-00607-7
Amal Mohamed Elmesiry, Amira Shahin Ibrahim, Hemmat A Elabd, Basma Mohamed El Naggar, Eman E Abd Elsalam, Mai Abd El Halim Moussa, Eman A Rageh, Mona Mokhtar, Muhammad M Harb, Aya H Elshazly, Mohamed A Khalafallah, Atef A Hassan
{"title":"Calibrated, explainable machine learning on routine laboratory data to characterize diagnostic assignment patterns in rheumatic diseases: a retrospective study of 12,085 patients.","authors":"Amal Mohamed Elmesiry, Amira Shahin Ibrahim, Hemmat A Elabd, Basma Mohamed El Naggar, Eman E Abd Elsalam, Mai Abd El Halim Moussa, Eman A Rageh, Mona Mokhtar, Muhammad M Harb, Aya H Elshazly, Mohamed A Khalafallah, Atef A Hassan","doi":"10.1186/s41927-025-00607-7","DOIUrl":"10.1186/s41927-025-00607-7","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":" ","pages":"10"},"PeriodicalIF":2.5,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2025-12-24DOI: 10.1186/s41927-025-00609-5
Khaled Aldhuaina, Khawla Alghanim
{"title":"Correction: Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis.","authors":"Khaled Aldhuaina, Khawla Alghanim","doi":"10.1186/s41927-025-00609-5","DOIUrl":"10.1186/s41927-025-00609-5","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"145"},"PeriodicalIF":2.5,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12729249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145826935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2025-12-23DOI: 10.1186/s41927-025-00610-y
Maram H Alshareef, Ghalia Almutair, Waleed Hafiz, Shoroug Ibrahim, Nahla H Hariri, Mokhtar Shatla
{"title":"Prevalence and predictors of fibromyalgia symptoms in an academic setting: a cross-sectional study.","authors":"Maram H Alshareef, Ghalia Almutair, Waleed Hafiz, Shoroug Ibrahim, Nahla H Hariri, Mokhtar Shatla","doi":"10.1186/s41927-025-00610-y","DOIUrl":"10.1186/s41927-025-00610-y","url":null,"abstract":"","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":" ","pages":"9"},"PeriodicalIF":2.5,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145817964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis.","authors":"Haimei Xu, Chen Li, Rui Ding, Yaoxuan Zhan, Haiyan Liu, Xintong Liang, Yuanchen Niu, Ying Luo, Zhiqin Hu, Jin He, Liming Chen, Tenghua Wang, Yi Fang","doi":"10.1186/s41927-025-00603-x","DOIUrl":"10.1186/s41927-025-00603-x","url":null,"abstract":"<p><strong>Objective: </strong>To compare the clinical efficacy and safety of biological disease-modifying antirheumatic drugs (DMARDs) and Janus kinase(JAK) inhibitors in patients with early rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>A systematic search was conducted of PubMed, Web of Science, Cochrane Library, and EMBASE databases (up to February 2025), supplemented by searches of clinical trial registries. Eligible randomised controlled trials enrolled adults with early RA (< 2 years) treated with biological DMARDs/JAK inhibitors versus conventional synthetic DMARDs. Statistical analyses were conducted using Stata software (version 16.0).</p><p><strong>Results: </strong>21 eligible trials involving nine interventions and 8,361 participants were included in this meta-analysis. Multiple biological DMARDs demonstrated superior therapeutic efficacy compared to methotrexate. Adalimumab + methotrexate showed the most pronounced effect on DAS28 remission (OR 2.90[95% CI 1.94-4.33]; SUCRA 83.7%), while tocilizumab + methotrexate exhibited the highest efficacy in achieving ACR70 response (OR 4.41[95% CI 2.29-8.49]; SUCRA 94.7%). Regarding safety, only tocilizumab + methotrexate demonstrated a higher incidence of adverse events(OR 5.11[95% CI 2.03-12.86]; SUCRA 0.6%). No safety risks were identified for other interventions. Due to the limited number of eligible clinical trials, the optimal treatment strategy remains inconclusive.</p><p><strong>Conclusion: </strong>For patients with early RA and high disease activity, combination therapy with certain biological DMARDs demonstrated superior clinical efficacy compared to methotrexate. No noteworthy safety risks have been observed. More high-quality trials should be conducted to evaluate treatment strategies for individuals with early RA comprehensively.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":" ","pages":"5"},"PeriodicalIF":2.5,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145686940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}